Dopamine is involved in the regulation of food intake, and obese persons have decreased dopamine D2 receptor availability in the striatum. Furthermore, midlife triceps skinfold thickness has been found to be positively associated with the risk of Parkinson's disease (PD) among Japanese-American men in Hawaii. The authors prospectively investigated whether obesity was associated with PD risk in two large cohorts of US men and women. They documented 249 cases of PD in men (1986)(1987)(1988)(1989)(1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000) and 202 cases in women . Neither baseline body mass index (weight (kg)/height (m) 2 ) nor early adult body mass index was associated with PD risk. The multivariate relative risk for a baseline body mass index of ≥30 versus <23 was 0.8 (95% confidence interval (CI): 0.6, 1.2; p for trend = 0.3). Overall, waist circumference and waist-to-hip ratio were not related to PD risk. However, among never smokers, both variables showed significantly positive associations with PD risk. The relative risks for comparisons of extreme quintiles were 1.9 (95% CI: 1.0, 3.4; p for trend = 0.03) for waist circumference and 2.0 (95% CI: 1.1, 3.6; p for trend = 0.03) for waist-to-hip ratio. The results do not support a role of overall obesity in PD pathogenesis; however, central obesity may be associated with higher PD risk among never smokers, and this finding merits further investigation. body composition; body mass index; obesity; Parkinson disease; prospective studies Abbreviations: BMI, body mass index; CI, confidence interval; HPFS, Health Professionals Follow-up Study; NHS, Nurses' Health Study; RR, relative risk.
was initiated in 1976 when 121,700 registered nurses aged 30-55 years provided detailed information on their medical history and lifestyle (9) . In both cohorts, followup questionnaires are mailed to participants every 2 years to obtain updated information on potential risk factors for chronic diseases and to ascertain whether any major medical events have occurred. A specific question on lifetime Parkinson's disease occurrence was first asked in 1988 for men and in 1994 for women, and a question on Parkinson's disease diagnosis within the previous 2 years was posed in the subsequent surveys. Participants were asked to report their height and current weight in 1986 (men) or 1976 (women), and body weight was updated every 2 years thereafter. The present investigation was restricted to men and women who provided baseline information on body weight and height, did not report symptoms of Parkinson's disease at baseline, and had not received a diagnosis of stroke or cancer (other than nonmelanoma skin cancer) before they answered the baseline questionnaire. We followed the eligible 47,700 men and 117,062 women from baseline to the date of occurrence of the first symptoms of Parkinson's disease, the date of death or stroke, or the end of follow-up (January 31, 2000, for men and May 31, 1998, for women), whichever occurred first. These studies were approved by the human subjects research committees at the Harvard School of Public Health and Brigham and Women's Hospital.
Parkinson's disease case ascertainment
Ascertainment of Parkinson's disease cases in these cohorts has been previously described (10) . Briefly, after obtaining permission from participants who reported a new diagnosis of Parkinson's disease, we asked the treating neurologist (or internist if the neurologist did not respond) to complete a questionnaire to confirm the diagnosis and the certainty of the diagnosis, or to send a copy of the medical record. A case was confirmed if a diagnosis of Parkinson's disease was considered definite or probable by the treating neurologist or internist, or if the medical record included either a final diagnosis of Parkinson's disease made by a neurologist or evidence at neurologic examination of at least two of the three cardinal signs (rest tremor, rigidity, bradykinesia) in the absence of features suggesting other diagnoses. The review of medical records was conducted by the investigators, blind to exposure status. Overall, the diagnosis was confirmed by the treating neurologist in 82.3 percent of the cases, by review of the medical records in 3.1 percent of the cases, and by the treating internist without further support in the remaining 14.6 percent of the cases.
Measurements of body weight and waist and hip circumferences
At baseline, participants in both cohorts were asked to report their height (in inches; 1 inch = 2.54 cm) and current body weight (in pounds; 1 pound = 0.45 kg), the latter of which was then updated biennially during follow-up. The HPFS 1986 questionnaire also elicited information on weight at age 21 years. In 1987, HPFS participants were asked in a supplementary questionnaire to measure their waist and hip circumferences (inches) with a paper tape and were given detailed measuring directions. In the NHS, weight at age 18 years was elicited in the 1980 questionnaire, and waist and hip circumferences were asked about in 1986. BMI was calculated as weight in kilograms divided by height squared in meters. Waist-to-hip ratio, calculated as waist circumference divided by hip circumference, was used as an indicator of central obesity along with waist circumference. Adult weight change was defined as baseline body weight minus weight at age 21 years in men or body weight in 1980 minus weight at age 18 years in women.
The validity of the self-reported weight data was high (the Pearson correlation coefficient was 0.98 in both cohorts), as evaluated among 123 HPFS and 140 NHS participants who were weighed twice 6-9 months apart by trained technicians (11) . The Pearson correlation coefficients for the correlation between self-reported and technician-measured waist circumference and waist-to-hip ratio were 0.98 and 0.77, respectively, in men and 0.91 and 0.75, respectively, in women (11) .
Statistical analyses
To minimize the potential effects of extreme values on regression analyses and to allow for nonlinear associations, we categorized all anthropometric variables before conducting the analyses and used the median value in each category to create a continuous variable for linear trend tests. Multivariate relative risks were calculated using Cox proportional hazards models, with adjustment for age, smoking, caffeine intake, and alcohol consumption. However, for the BMI analyses in women, only age-and smoking-adjusted relative risks are reported. Information on alcohol consumption and caffeine intake was not collected at baseline (1976) in women, and further adjustment for these two variables as derived from the first dietary assessment in 1980 did not change the risk estimates. We weighted log relative risks from the two cohorts by the inverse of their variances to obtain a pooled relative risk. We calculated 95 percent confidence intervals for all relative risks, and all p values were two-tailed (α = 0.05).
Since Parkinson's disease patients may begin to lose weight several years prior to diagnosis (12), we used the anthropometric variables measured at baseline in primary analyses. To further exclude the possibility that weight loss early in the course of the disease might bias our results, we repeated the analyses after excluding the first 3 or 4 years of follow-up. In secondary analyses, we related each biennially updated BMI to the incidence of Parkinson's disease in the following 2 years of follow-up.
Previous analyses of the HPFS cohort showed that BMI peaked at the age of 60-65 years and then declined, whereas waist circumference and waist-to-hip ratio increased across all age groups (13) . For this reason, as well as to make our data more comparable with those of the Hawaiian study (7) , in which all participants were younger than 68 years (mean age = 54 years; range, 45-68 years), we further conducted the analyses in men according to age at baseline (<65 years vs. ≥65 years). No age-subgroup analyses were performed in women, because the women were all younger than 55 years at recruitment. Finally, we conducted separate analyses in never smokers and ever smokers because smoking was related to both body weight and Parkinson's disease risk.
RESULTS
We documented a total of 249 Parkinson's disease cases in men and 202 cases in women during follow-up. The average age at which the first symptom of Parkinson's disease was BMI in early adulthood (age 21 years in men and age 18 years in women) was not associated with later risk of Parkinson's disease; the relative risk was 1.0 in both men and women when we compared participants whose BMI was 27 or more with those whose BMI was less than 20. A nonsignificantly higher risk (RR = 1.5, 95 percent CI: 0.9, 2.3) was found among men with weight gains of 45 or more pounds from early adulthood to baseline as compared with men who gained less than 5 pounds; however, this comparison in women showed a nonsignificantly lower risk (RR = 0.7, 95 percent CI: 0.4, 1.2). In neither men nor women was the linear trend test associated with weight gain statistically significant.
Neither waist circumference nor waist-to-hip ratio was associated with risk of Parkinson's disease in men (table 2) , and the results remained the same after further adjustment for BMI. Women in the lowest quintile of waist circumference (<28.0 inches) had the lowest risk of Parkinson's disease, and women in the second (28.0-29.9 inches) and fourth (32.0-34.9 inches) quintiles had marginally significant increases in Parkinson's disease risk (RR = 2.1 (95 percent CI: 1.0, 4.6) and RR = 2.1 (95 percent CI: 1.0, 4.5), respectively) (table 2). After controlling for BMI, the rela- No significant interactions were found between baseline anthropometric measurements and age in men, although among younger men a slightly higher risk was found when comparing the extreme categories of BMI (RR = 1.3, 95 percent CI: 0.6, 2.7) (table 3), while a slightly lower risk was found among older men (RR = 0.7, 95 percent CI: 0.3, 1.8).
The results for waist circumference and waist-to-hip ratio were also comparable between younger men and older men.
The subgroup analyses of BMI by smoking status showed no difference between never smokers and ever smokers (table 4) . However, a significant effect of interaction between waist circumference and smoking status on Parkinson's disease risk was found in pooled analyses (p = 0.04), and the interaction between waist-to-hip ratio and smoking status was marginally significant (p = 0.09). Among never smokers, greater waist circumference or waistto-hip ratio was associated with higher Parkinson's disease risk in both men and women. In comparison with the lowest quintile, the pooled relative risks for quintiles 2-5 of waist circumference were 1.6, 1.6, 2.5, and 1.9 (p for trend = 0.03). The corresponding relative risks for waist-to-hip ratio were 1.3, 2.4, 1.8, and 2.0 (p for trend = 0.03), respectively. The results were similar after further adjustment for BMI: The pooled relative risks for quintiles 2-5 were 1.6, 1.5, 2.4, and 2.0, respectively, for waist circumference (p for trend = 0.06) and 1.3, 2.2, 1.7, and 1.9, respectively, for waist-to-hip ratio (p for trend = 0.06). Neither waist circumference nor waistto-hip ratio was associated with risk of Parkinson's disease in ever smokers (p values for trend were 0.3 and 0.7, respectively, in the pooled analyses). After further adjustment for BMI, the relative risks associated with higher waist circumference quintiles increased among female smokers (RRs for quintiles 2-5: 2.1, 1.1, 2.0, and 2.8; p for trend = 0.2), but BMI adjustment made no difference in the risk estimates for waist-to-hip ratio among female smokers or for either variable in male smokers.
DISCUSSION
In participants from these large prospective cohort studies, we did not find significant associations between BMI, waist circumference, or waist-to-hip ratio and risk of Parkinson's disease for either men or women. However, greater waist circumference and waist-to-hip ratio were related to higher risk of Parkinson's disease among never smokers.
Both the HPFS and the NHS are prospectively designed studies with long follow-up periods, allowing us to rule out the effect of preclinical weight change via lag-time analyses. The self-reported anthropometric information in both cohorts has been validated previously (11) and has been successfully used to investigate associations between obesity and the risks of major chronic diseases, including cardiovascular disease, type II diabetes mellitus, and cancer (13) (14) (15) (16) (17) (18) .
To our knowledge, only one prospective epidemiologic study has examined the relation between obesity and risk of Parkinson's disease. A total of 137 Parkinson's disease cases were identified among 7,990 Japanese-American men in Honolulu, Hawaii, with 30 years of follow-up (7) . In that population, a strong positive association was found between triceps skinfold thickness and Parkinson's disease risk. Compared with the lowest quartile of triceps skinfold thickness, the multivariate relative risk for the highest quartile was 2.8 (95 percent CI: 1.4, 5.6; p for trend < 0.001). Higher Parkinson's disease incidence was also found when higher quartiles of BMI or subscapular skinfold thickness were compared with the lowest quartile; however, in both cases, the test for linear trend was not statistically significant (p for trend = 0.1). We did not have measures of peripheral obesity in our study, and thus we were unable to determine the relative importance of peripheral obesity in the etiology of Parkinson's disease. We did not find any significant associations between BMI and Parkinson's disease risk, even after restricting our analysis to men younger than 65 years of age, a population with an age composition comparable to that of the men in the Hawaiian study (7) . In women, higher BMI was associated with nonsignificantly lower risk of Parkinson's disease. A statistically significant inverse association was found between the biennially updated BMI and risk of Parkinson's disease. Previous investigations have suggested that Parkinson's disease patients tend to lose weight (19, 20) , and we further found that these weight losses are likely to begin 2-4 years prior to diagnosis (12) . Thus, the inverse association between updated BMI and Parkinson's disease risk is likely to reflect the preclinical weight loss. Therefore, our results do not support an important role for overall obesity in determining susceptibility to Parkinson's disease.
Obesity is a well-known risk factor for coronary heart disease and type II diabetes. Previous investigations have suggested that abdominal obesity, as measured by waist circumference or waist-to-hip ratio, increases the risk of these diseases independently of overall obesity (13) (14) (15) . Our current investigation suggests that abdominal obesity may increase Parkinson's disease risk among nonsmokers. The highest quintile of waist circumference or waist-to-hip ratio was associated with an approximately twofold increased risk over the lowest quintile, with a statistically significant trend. Although we could not exclude the possibility that these findings were due to chance or residual confounding, positive associations were present in both men and women and were controlled for known Parkinson's disease risk factors. The fact that we did not find such a positive association among ever smokers may be explained by the strong inverse association between smoking and Parkinson's disease (21) (22) (23) . In animal models of Parkinson's disease, cigarette smoke and nicotine could attenuate the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (24-26). Therefore, it may be hypothesized that, among smokers, the adverse effect on Parkinson's disease associated with (27) . Pesticides or herbicides such as rotenone and paraquat cause dopaminergic neuron death and/or induce parkinsonism in animal models (28, 29) , and the use of pesticides and residence in rural areas have been linked to increased Parkinson's disease risk in epidemiologic investigations (30) . Adipose tissue may serve as a reservoir for lipidsoluble environmental neural toxicants, and visceral fat is more metabolically active and thus probably more ready for chronic neurotoxin release.
A recent clinical observation showed that extremely obese persons had a significantly lower availability of dopamine D2 receptor in the striatum than nonobese controls (4) . A proposed explanation is that obesity down-regulates dopamine D2 receptor to compensate for the increased dopamine concentration associated with eating (1, 2, 4). Alternatively, one can speculate that lower dopamine D2 receptor availability may lead to overeating and obesity (31) . In either case, the lower dopamine D2 receptor availability may predispose obese persons to later higher Parkinson's disease risk. As Abbott et al. (7) speculated, there might be a compensatory increase in dopamine turnover among obese persons, which may induce oxidative stress and dopaminergic neuron death. Finally, obesity may be associated with low-grade chronic and systematic inflammation that may in turn increase the risk of Parkinson's disease (32) . Interpretation of our results should consider the potential limitations of this study. We relied on the judgment of the patients' treating physicians (in most cases, their neurologist) for the Parkinson's disease diagnosis. Since these cases were not pathologically confirmed, we cannot exclude the possibility that a few of them were misdiagnosed. In earlier studies, approximately 24 percent of the clinically diagnosed Parkinson's disease cases could not be confirmed upon pathologic examination (33, 34) ; however, diagnostic accuracy has improved to 90 percent or higher in most recent clinicopathologic studies (35, 36) . Furthermore, the incidence rates of our study are comparable to those reported by other investigators (37) (38) (39) (40) , and we have previously reported in these cohorts the well-recognized inverse associations between cigarette smoking (21) and caffeine consumption (10, 41) and Parkinson's disease risk. This provides, albeit indirectly, evidence against substantial diagnostic misclassification in our cohorts. Some misclassification of exposure variables is inevitably present in observational studies. According to our validation study (11) , random measurement error was higher for waist-to-hip ratio, and therefore the relative risk corresponding to this exposure may have been underestimated. Participants in our cohorts were welleducated health professionals who had average BMIs of 25.5 (men) and 23.8 (women) at baseline; few of them had a BMI greater than 35 (1.4 percent in men and 2.2 percent in women). Therefore, our results may not be applicable to persons who are extremely obese.
In summary, the results of our study suggest that overall obesity does not increase the risk of Parkinson's disease. Among nonsmokers, abdominal obesity may be a risk factor for Parkinson's disease, and this association warrants further investigation.
